ljpmedical
ljpmedical is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ljpmedical.
ljpmedical is a company.
Key people at ljpmedical.
Lympha Press, LLC (formerly Medical Solutions Supplier, often associated with "ljpmedical" branding) is a U.S.-based durable medical equipment company specializing in pneumatic compression devices for treating chronic conditions like lymphedema, venous disease, and lipedema.[1] It serves patients and clinical partners by providing clinically proven, easy-to-use home therapy products that adapt to changing patient needs, improving adherence and outcomes through vertical integration for enhanced offerings and expanded reach.[1]
The company builds and distributes devices from the Lympha Press line, originally developed by Mego Afek AC LTD. in 1978 in collaboration with vascular surgery experts.[1] It addresses unmet needs in managing swelling and circulation disorders, with over 30 years of U.S. market leadership via its associate network, focusing on patient-centered care and scalability.[1]
Founded 30 years ago as Medical Solutions Supplier (MSS), the company was established by Steve Kantor with a niche focus on improving lives for patients with lymphedema, venous disease, and lipedema.[1] Kantor's vision emphasized specialized durable medical equipment, earning MSS awards and flagship status in the Lympha Press Associate Network.[1]
A pivotal ownership transition led to its rebranding as Lympha Press, LLC, under CEO Joseph Carberry, enabling vertical integration with parent innovator Mego Afek (founded 1962).[1] Mego Afek pioneered the Lympha Press devices in 1978 with Professor Avigdor Zelikovski, shifting from industrial gauges to lymphedema therapies, which MSS scaled in the U.S. market for sustained growth.[1]
(Note: Other "LJP"-prefixed entities like La Jolla Pharmaceutical—developer of drugs like LJP-394 and Giapreza—or unrelated care providers like LJP Wellbeing appear in searches but do not match "ljpmedical" as a cohesive company; Lympha Press aligns most directly via medical equipment context.[1][3][5][6])
Lympha Press rides the wave of home-based chronic disease management, fueled by aging populations and post-pandemic demand for non-invasive, patient-adherent therapies amid rising lymphedema prevalence (affecting millions globally).[1] Timing is ideal with vertical integration enabling scalability in the $5B+ compression therapy market, where medtech shifts toward adaptive, user-friendly devices reduce hospital reliance.[1]
Market forces like clinician endorsements and home care trends favor it, as pneumatic compression outperforms manual methods in outcomes.[1] It influences the ecosystem by expanding access via networks, supporting underserved venous/lipedema patients, and modeling integrated medtech for similar niches.[1]
Lympha Press is poised for U.S. and global expansion through scaled vertical operations, targeting larger geographies with enhanced devices amid growing chronic care needs.[1] Trends like AI-adaptive pumps and telehealth integration could amplify its edge, while reimbursement expansions for home therapies shape growth.
Its influence may evolve from niche leader to mainstream provider, humanizing medtech by prioritizing patient outcomes—echoing Kantor's founding mission to transform lives for those with debilitating swelling disorders.[1]
Key people at ljpmedical.
